Psychedelics are serotonin 2A receptor agonists that can lead to profound changes in
perception, cognition and mood. In this review, we focus on the basic neurobiology …

Classic psychedelics, such as LSD, psilocybin, and the DMT-containing beverage
ayahuasca, show some potential to treat depression, anxiety, and addiction. Importantly …

Psilocybin is a serotonergic psychedelic with untapped therapeutic potential. There are hints
that the use of psychedelics can produce neural adaptations, although the extent and …

Clinical studies suggest the therapeutic potential of psychedelics, including ayahuasca,
DMT, psilocybin, and LSD, in stress-related disorders. These substances induce cognitive …

The emerging therapeutic efficacy of ketamine and classical psychedelics for depression
has inspired tremendous interest in the underlying neurobiological mechanisms. We review …

A single dose of psilocybin, a psychedelic that acutely causes distortions of space–time
perception and ego dissolution, produces rapid and persistent therapeutic effects in human …

4-Phosphoryloxy-N, N-dimethyltryptamine (psilocybin) is a naturally occurring tertiary amine
found in many mushroom species. Psilocybin is a prodrug for 4-hydroxy-N, N …

In addition to producing profound subjective effects following acute administration,
psychedelic compounds can induce beneficial behavioral changes relevant to the treatment …

Clinical studies provide evidence that ketamine and psilocybin could be used as fast-acting
antidepressants, though their mechanisms and toxicity are still not fully understood. To …

Psychedelic drugs have reemerged as tools to treat several brain disorders. Cultural
attitudes toward them are changing, and scientists are once again investigating the neural …